How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

101,093 results for

Breast Cancer

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Ogivri for Early Breast Cancer / Metastatic Breast Cancer / Metastatic Gastric Cancer Biosimilar – Details

Ogivri for Early Breast Cancer / Metastatic Breast Cancer / Metastatic Gastric Cancer Biosimilar – Details Ogivri for Early Breast Cancer / Metastatic Breast Cancer / Metastatic Gastric Cancer Biosimilar – Details | CADTH.ca Find the information you need Ogivri for Early Breast Cancer / Metastatic Breast Cancer / Metastatic Gastric Cancer Biosimilar – Details Ogivri for Early Breast Cancer / Metastatic Breast Cancer / Metastatic Gastric Cancer Biosimilar – Details Project Number pCODR 10169 (...) Brand Name Ogivri Generic Name Trastuzumab Strength 150 mg/vial and 440 mg/vial Tumour Type Breast / Gastrointestinal Indication Early Breast Cancer / Metastatic Breast Cancer / Metastatic Gastric Cancer Biosimilar Funding Request For the treatment of patients with early stage breast cancer with ECOG 0-1 status, whose tumours overexpress HER2, following surgery and after chemotherapy, following adjuvant chemotherapy consisting of doxorubicin and cyclophosphamide, in combination with paclitaxel

2019 CADTH - Pan Canadian Oncology Drug Review

2. Magnetic Resonance Imaging as an Adjunct to Mammography for Breast Cancer Screening in Women at Less Than High Risk for Breast Cancer

Magnetic Resonance Imaging as an Adjunct to Mammography for Breast Cancer Screening in Women at Less Than High Risk for Breast Cancer Magnetic Resonance Imaging as an Adjunct to Mammography for Breast Cancer Screening in Women at Less Than High Risk for Breast Cancer - Health Quality Ontario (HQO) Let's make our health system healthier Open Menu Quick Links Search Search A A A Evidence to Improve Care Share: Magnetic Resonance Imaging as an Adjunct to Mammography for Breast Cancer Screening (...) in Women at Less Than High Risk for Breast Cancer Ontario Health Technology Advisory Committee Recommendation The Ontario Health Technology Advisory Committee recommends against publicly funding screening breast magnetic resonance imaging (MRI) as an adjunct to screening mammography for women who are at less than high risk for breast cancer and who have no personal history of breast cancer Breast cancer is the most common cancer among Canadian women. The most common form of screening for breast cancer

2017 Health Quality Ontario

3. Breast surgery for metastatic breast cancer. (PubMed)

Breast surgery for metastatic breast cancer. Metastatic breast cancer is not a curable disease, but women with metastatic disease are living longer. Surgery to remove the primary tumour is associated with an increased survival in other types of metastatic cancer. Breast surgery is not standard treatment for metastatic disease, however several recent retrospective studies have suggested that breast surgery could increase the women's survival. These studies have methodological limitations (...) including selection bias. A systematic review mapping all randomised controlled trials addressing the benefits and potential harms of breast surgery is ideal to answer this question.To assess the effects of breast surgery in women with metastatic breast cancer.We conducted searches using the MeSH terms 'breast neoplasms', 'mastectomy', and 'analysis, survival' in the following databases: the Cochrane Breast Cancer Specialised Register, CENTRAL, MEDLINE (by PubMed) and Embase (by OvidSP) on 22 February

2018 Cochrane

4. Magnetic resonance imaging as an adjunct to mammography for breast cancer screening in women atless than high risk for breast cancer: a health technology assessment

Magnetic resonance imaging as an adjunct to mammography for breast cancer screening in women atless than high risk for breast cancer: a health technology assessment Magnetic resonance imaging as an adjunct to mammography for breast cancer screening in women at less than high risk for breast cancer: a health technology assessment Magnetic resonance imaging as an adjunct to mammography for breast cancer screening in women at less than high risk for breast cancer: a health technology assessment (...) Health Quality Ontario Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Health Quality Ontario. Magnetic resonance imaging as an adjunct to mammography for breast cancer screening in women at less than high risk for breast cancer: a health technology assessment. Toronto: Health Quality Ontario (HQO). Ontario health technology assessment series

2017 Health Technology Assessment (HTA) Database.

5. Magnetic resonance imaging as an adjunct to mammography for breast cancer screening in women at less than high risk for breast cancer: OHTAC recommendation

Magnetic resonance imaging as an adjunct to mammography for breast cancer screening in women at less than high risk for breast cancer: OHTAC recommendation Magnetic resonance imaging as an adjunct to mammography for breast cancer screening in women at less than high risk for breast cancer: OHTAC recommendation Magnetic resonance imaging as an adjunct to mammography for breast cancer screening in women at less than high risk for breast cancer: OHTAC recommendation Health Quality Ontario Record (...) Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Health Quality Ontario. Magnetic resonance imaging as an adjunct to mammography for breast cancer screening in women at less than high risk for breast cancer: OHTAC recommendation. Toronto: Health Quality Ontario (HQO). 2016 Authors' conclusions The Ontario Health Technology Advisory Committee (OHTAC

2017 Health Technology Assessment (HTA) Database.

6. Paclitaxel (Pazenir) - metastatic breast cancer, non-small cell lung cancer

Paclitaxel (Pazenir) - metastatic breast cancer, non-small cell lung cancer Official address Domenico Scarlattilaan 6 ? 1083 HS Amsterdam ? The Netherlands An agency of the European Union Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 © European Medicines Agency, 2019. Reproduction is authorised provided the source is acknowledged. EMA/159292/2019 EMEA/H/C/004441 Pazenir (paclitaxel (...) ) An overview of Pazenir and why it is authorised in the EU What is Pazenir and what is it used for? Pazenir is used to treat the following cancers in adults: • metastatic breast cancer, when the first treatment has stopped working and standard treatment including an ‘anthracycline’ (another type of cancer medicine) is not suitable. ‘Metastatic’ means that the cancer has spread to other parts of the body; • non-small cell lung cancer, as a first treatment in combination with the cancer medicine carboplatin

2019 European Medicines Agency - EPARs

7. Trastuzumab (Ogivri) - breast cancer or stomach cancer

Trastuzumab (Ogivri) - breast cancer or stomach cancer 1 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 2 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions 1. NAME OF THE MEDICINAL PRODUCT Ogivri 150 mg powder for concentrate for solution for infusion 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One (...) for solution for infusion (powder for concentrate). White to pale yellow lyophilised powder. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Breast cancer Metastatic breast cancer Ogivri is indicated for the treatment of adult patients with HER2 positive metastatic breast cancer (MBC): - as monotherapy for the treatment of those patients who have received at least two chemotherapy regimens for their metastatic disease. Prior chemotherapy must have included at least an anthracycline and a taxane unless

2019 European Medicines Agency - EPARs

8. Persistent breast pain in post-surgery breast cancer survivors and women with no history of breast surgery or cancer: associations with pain catastrophizing, perceived breast cancer risk, breast cancer worry, and emotional distress. (PubMed)

Persistent breast pain in post-surgery breast cancer survivors and women with no history of breast surgery or cancer: associations with pain catastrophizing, perceived breast cancer risk, breast cancer worry, and emotional distress. Persistent breast pain (PBP) is prevalent among breast cancer survivors and has powerful negative psychological consequences. The present study provided a first test of the hypothesis that: (a) pain catastrophizing, (b) heightened perceived risk of cancer, and (c (...) ) worry that pain indicates cancer may be independent mediating links between breast cancer survivors' experiences of PBP and heightened emotional distress.We assessed levels of PBP and psychological factors in breast cancer survivors (Survivor Group: n = 417; Stages I-IIIA; White = 88.7%; Age M = 59.4 years) at their first surveillance mammogram post-surgery (6-15 months). A comparison group of women without histories of breast surgery or cancer (Non-cancer Group: n = 587; White = 78.7%; Age M = 57.4

Full Text available with Trip Pro

2019 Acta Oncologica

9. Whole breast irradiation with supraclavicular fossa radiotherapy and axillary radiotherapy for people with early breast cancer following a macrometastatic sentinel node biopsy

Whole breast irradiation with supraclavicular fossa radiotherapy and axillary radiotherapy for people with early breast cancer following a macrometastatic sentinel node biopsy Axillary radiotherapy - Health Technology Wales > Axillary radiotherapy Axillary radiotherapy Topic Status Complete Whole breast irradiation with supraclavicular fossa radiotherapy and axillary radiotherapy for people with early breast cancer following a macrometastatic sentinel node biopsy. Summary This report (...) was prepared by Health Technology Wales and Cedar (Cardiff & Vale University Health Board) on behalf of Velindre Cancer Centre. It summarises the existing evidence on the technology of interest to support a prioritisation discussion related to the implementation of radiotherapy procedures/techniques at Velindre Cancer Centre. Topic Exploration Report TER030 (03.2019) TER Access our guidance Our advice documents are free to download, but we would be grateful if you could help us improve our services

2019 Health Technology Wales

10. Partial breast irradiation for people with early breast cancer

Partial breast irradiation for people with early breast cancer Partial breast irradiation - Health Technology Wales > Partial breast irradiation Partial breast irradiation Topic Status Complete Partial breast irradiation for people with early breast cancer. Summary This report was prepared by Health Technology Wales and Cedar (Cardiff & Vale University Health Board) on behalf of Velindre Cancer Centre. It summarises the existing evidence on the technology of interest to support a prioritisation (...) discussion related to the implementation of radiotherapy procedures/techniques at Velindre Cancer Centre. Topic Exploration Report TER029 (03.2019) TER Access our guidance Our advice documents are free to download, but we would be grateful if you could help us improve our services by telling us why you are looking at our advice and how you intend to use it. Full Name Job Title Organisation Email I'm looking at this document because We may like to contact you by email to find out more about how you used

2019 Health Technology Wales

11. Neratinib (Nerlynx) - Breast cancer, breast neoplasms

Neratinib (Nerlynx) - Breast cancer, breast neoplasms 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2018. Reproduction is authorised provided the source is acknowledged. 13 July 2018 EMA/CHMP/525204/2018 Committee for Medicinal Products for Human Use (CHMP) Assessment report Nerlynx International (...) disease-free survival DFS-DCIS disease-free survival including ductal carcinoma in situ ECG electrocardiogram ECOG Eastern Cooperative Oncology Group EGFR epidermal growth factor receptor EQ-5D EuroQol 5-Dimension Questionnaire ER estrogen receptor ERBB erythroblastic leukemia viral oncogene homolog; also termed HER ExteNET Extended Adjuvant Treatment of Breast Cancer with Neratinib FACT-B Functional Assessment of Cancer Therapy-Breast FMO flavin-containing monooxygenase GI gastrointestinal HER human

2018 European Medicines Agency - EPARs

12. Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer

Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer Familial breast cancer: classification, care Familial breast cancer: classification, care and managing breast cancer and related and managing breast cancer and related risks in people with a family history of risks in people with a family history of breast cancer breast cancer Clinical guideline Published: 25 June 2013 nice.org.uk/guidance/cg164 © NICE 2018 (...) NICE recommendations wherever possible. Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer (CG164) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 48Contents Contents Overview 4 Who is it for? 4 Recommendations 5 1.1 Clinical significance of a family history of breast cancer 5 1.2 Information and support 8 1.3 Care

2013 National Institute for Health and Clinical Excellence - Clinical Guidelines

13. Magnetic Resonance Imaging as an Adjunct to Mammography for Breast Cancer Screening in Women at Less Than High Risk for Breast Cancer

Magnetic Resonance Imaging as an Adjunct to Mammography for Breast Cancer Screening in Women at Less Than High Risk for Breast Cancer Health Technology Assessment - Health Quality Ontario (HQO) Let's make our health system healthier Open Menu Quick Links Search Search A A A Evidence to Improve Care Share: Health Technology Assessment To continuously improve the quality of health care in Ontario, we use established scientific methods to analyze evidence and develop assessments of new

2016 Health Quality Ontario

14. An international randomised controlled trial to compare TARGeted Intraoperative radioTherapy (TARGIT) with conventional postoperative radiotherapy after breast-conserving surgery for women with early-stage breast cancer (the TARGIT-A trial) (PubMed)

An international randomised controlled trial to compare TARGeted Intraoperative radioTherapy (TARGIT) with conventional postoperative radiotherapy after breast-conserving surgery for women with early-stage breast cancer (the TARGIT-A trial) An international randomised controlled trial to compare TARGeted Intraoperative radioTherapy (TARGIT) with conventional postoperative radiotherapy after breast-conserving surgery for women with early-stage breast cancer (the TARGIT-A trial) Journals Library (...) An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website search above to find the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> 1)"> {{metadata.Title}} {{metadata.Headline}} After conservative breast surgery for early breast cancer, targeted intra-operative radiotherapy was non-inferior in terms of local

Full Text available with Trip Pro

2016 NIHR HTA programme

15. Improvement in risk prediction, early detection and prevention of breast cancer in the NHS Breast Screening Programme and family history clinics: a dual cohort study

Improvement in risk prediction, early detection and prevention of breast cancer in the NHS Breast Screening Programme and family history clinics: a dual cohort study Improvement in risk prediction, early detection and prevention of breast cancer in the NHS Breast Screening Programme and family history clinics:a dual cohort study Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could

Full Text available with Trip Pro

2016 NIHR HTA programme

16. Individualising breast cancer treatment to improve survival and minimise complications in older women: a research programme including the PLACE RCT

Individualising breast cancer treatment to improve survival and minimise complications in older women: a research programme including the PLACE RCT Individualising breast cancer treatment to improve survival and minimise complications in older women: a research programme including the PLACE RCT Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page (...) from the navigation or try a website search above to find the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> 1)"> {{metadata.Title}} {{metadata.Headline}} This research programme on individualising breast cancer treatment for older women included the PLACE trial for arm lymphoedema, which closed early, but has not reported yet. {{author}} {{($index , , , , , , , & . Nigel Bundred 1, 2, * , Chris Todd 3 , Julie Morris 1, 2, 4 , Vaughan Keeley 5 , Arnie Purushotham 6

2019 NIHR HTA programme

17. Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer: a systematic review and economic analysis

Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer: a systematic review and economic analysis Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer: a systematic review and economic analysis Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website

2019 NIHR HTA programme

18. Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer

Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer Ribociclib with fulv Ribociclib with fulvestr estrant for treating ant for treating hormone receptor-positiv hormone receptor-positive, e, HER2-negativ HER2-negative, advanced breast cancer e, advanced breast cancer T echnology appraisal guidance Published: 14 August 2019 www.nice.org.uk/guidance/ta593 © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk (...) to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer (TA593) © NICE 2019. All rights

2019 National Institute for Health and Clinical Excellence - Technology Appraisals

19. Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy

Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy Abemaciclib with fulv Abemaciclib with fulvestr estrant for treating ant for treating hormone receptor-positiv hormone receptor-positive, e, HER2-negativ HER2-negative advanced breast cancer e advanced breast cancer after endocrine ther after endocrine therap apy y T echnology appraisal guidance Published: 8 May 2019 www.nice.org.uk/guidance/ta579 © NICE 2019. All (...) -negative advanced breast cancer after endocrine therapy (TA579) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 19Contents Contents 1 Recommendations 4 2 Information about abemaciclib 6 3 Committee discussion 7 New treatment option 7 Clinical management 8 Clinical evidence 8 Adverse effects 9 Network meta-analysis 10 The company's economic model 10 Utility values in the economic model 12 Subsequent treatments

2019 National Institute for Health and Clinical Excellence - Technology Appraisals

20. Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer

Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer P Pertuzumab for adjuvant treatment of ertuzumab for adjuvant treatment of HER2-positiv HER2-positive early stage breast cancer e early stage breast cancer T echnology appraisal guidance Published: 20 March 2019 nice.org.uk/guidance/ta569 © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility (...) equality of opportunity and to reduce health inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer (TA569) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2

2019 National Institute for Health and Clinical Excellence - Technology Appraisals

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>